JP Morgan Chase
ADPT icon

JP Morgan Chase’s Adaptive Biotechnologies ADPT Stock Holding History

JP Morgan Chase’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-108,000
Closed -$4.35M – 6309
2021
Q1 		$4.35M Buy
+108,000
New +$5.85M ﹤0.01% 3092

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

JP Morgan Chase's ADPT Position: Q1 2026 in Review

JP Morgan Chase reduced its Adaptive Biotechnologies (ADPT) stake by 2.5% in Q1 2026, selling an estimated $105K and leaving 259,176 shares worth $3.33M. The position accounts for ﹤0.01% of the portfolio, ranked #3689.

JP Morgan Chase first reported a position in ADPT in Q2 2019 and has held it in 28 quarters since. The position peaked at $78.4M in Q4 2020. 295 funds tracked by Wall St. Rank hold ADPT as of Q1 2026.

  • JP Morgan Chase held 259,176 shares of Adaptive Biotechnologies worth $3.33M as of Q1 2026.
  • JP Morgan Chase sold 6,575 Adaptive Biotechnologies shares in Q1 2026, an estimated $105K.
  • Adaptive Biotechnologies made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #3689 holding.
  • JP Morgan Chase first reported a position in Adaptive Biotechnologies in Q2 2019 and has held it in 28 quarters since.
  • JP Morgan Chase's Adaptive Biotechnologies position peaked at $78.4M in Q4 2020.
  • 295 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.